

Business Consortium

 **Mission of AABC**

The mission of Alzheimer's Association Business Consortium (AABC) is to advance Alzheimer's disease research and innovation in small- and medium-size biotechnology, diagnostics, medical device and contract research organizations.

AABC members work in areas of common interest precompetitively to advance both the field of Alzheimer's research and the goals of its member organizations. They provide leadership and direction to the group's areas of focus, which include, but are not limited to, collaborations, recognition and visibility, and knowledge and information sharing. AABC welcomes new members who are aligned in their commitment to research and innovation. To express interest in joining, please email Dr. Leen Kawas (kawas@m3bio.com), co-chair; Dr. Judy Walker (jwalker@cerecin.com), co-chair; or Dr. Rebecca Edelmayer (rmedelmayer@alz.org), facilitator.

 **Congratulations to the New AABC Co-Chair**

Congratulations to Dr. Judy Walker, who was elected as the new AABC co-chair. She will serve a two-year term. Dr. Walker is the chief medical officer at Cerecin, and we are delighted to have her serving in this role.

The Alzheimer's Association extends its gratitude to Dr. Kira Sheinerman for her service to the AABC. Under her leadership, AABC has grown in membership and has hosted events propelling the mission. We'd also like to thank our two other co-chair candidates, Dr. Marcel Alavi of 712 North and Dr. Maria Maccacchini of QR Pharma. We know they will continue to provide important leadership contributions to the AABC. We look forward to working with the two AABC co-chairs, Dr. Walker and Dr. Kawas, in the upcoming year and would like to thank everyone for your continued participation.

 **Welcome New Members**

AABC is growing! We welcome these new members:

- » **Eran Ferri – BioEye**
BioEye provides monitoring for early detection of cognitive decline via a mobile eye tracking screening method. [Read more.](#)
- » **Paul Slowey – Oasis Diagnostics Corporation**
Oasis Diagnostics develops noninvasive, saliva-based technology for rapid testing, sample collection and molecular diagnostics. [Read more.](#)
- » **Rick Morris – GaitIQ**
GaitIQ is an early-stage digital health software at a service company that developed an app to measure a patient's gait. [Read more.](#)

 **News from AABC members and growth AD companies****AiCure's Revenue Soars as it Bolsters Client List and Executive Team**

AiCure, a behavioral data analytics company targeting the health care and life sciences industries, announced its revenue growth more than doubled year over year from 2017. This growth comes from a significant client increase, having added eight leading biotechnology and pharmaceutical clients to its roster over the past year. In addition, AiCure added four industry veterans to its management and board of directors teams. With these milestones, AiCure will continue to deliver on its commitment to improve health by understanding the science behind the human response to illness and treatment. [Read more.](#)



AABC Translational Animal Models Think Tank

The AABC Translation Animal Models Group, chaired by Joseph Araujo, Intervivo Solutions, and facilitated by Rebecca Edelmayer, Alzheimer's Association, in collaboration with MODEL-AD members held a think tank in Washington, D.C., Nov. 28-29, 2018. The think tank was a shoulder meeting to the Alzheimer's Association Research Roundtable and was well attended. The agenda consisted of sessions addressing proteomics, genomics and metabolomics, modern behavioral models, and translational, experimental and operational issues. The think tank proceedings will be submitted for publication.



Funding Opportunities

NIA's Office of Small Business Research (SBIR) has significantly increased its funding and has a call for applications for numerous grants. The next deadlines for submission are April 5 and Sept. 5. [Read more.](#)



Upcoming Events

Webinar: AABC Ask the Expert – CEO Panel

Date/Time: Thursday, April 25, 11 a.m. ET.

Topic: CEO Panel

This webinar will feature Kira Sheinerman, Ph.D., MBA, DiamiR, Charles Stacey, M.D., Cerecin, and Ken Moch, MBA, Cognition Therapeutics, discussing their experiences, challenges and best practices as CEOs of companies in diverse Alzheimer's research and different stages of company development.

To join the meeting on a computer or mobile phone: <https://bluejeans.com/936121156?src=calendarLink>

A few best practices will ensure your meeting is a success:

1. Use a headset or earbuds for the best audio experience and mute yourself when not speaking.
2. Make sure you have a solid internet connection.
3. Ensure you have good camera angle and adequate lighting... and don't forget to smile!

Phone Dial-in

+1.888.240.2560 (U.S. Toll Free)

Meeting ID: 936 121 156

(Global Numbers: <http://bluejeans.com/premium-numbers>)

Meeting ID: 936 121 156

Neuro4D Conference 2019: International Conference on Neurodegenerative Disease Drug Discovery

Date: May 13-14

Location: Favorite Park Hotel – Mainz- Germany

The Neuro4D is an international conference on neurodegenerative disease drug discovery bringing together drug discovery companies, service and technology providers, and academic innovators in the field of proteopathic neurodegenerative diseases such as Alzheimer's dementia and Parkinson's disease, etc. [Conference information.](#)

AAIC Workshop: Commercializing a Novel Therapeutic Target for Alzheimer's Disease

Date: Saturday, July 13

Location: Los Angeles, CA

The Alzheimer's Association International Conference® 2019 (AAIC®) is hosting a preconference workshop (separate registration fee from AAIC) that the AABC membership is encouraged to attend. This workshop will address key considerations and challenges when starting a new company. [Read more.](#)



Upcoming Events (Cont.)

Save the Date: AABC In-Person Meeting at AAIC

Date: Monday, July 15

Time: Noon-2 p.m.

Location: TBD



Past Events

Webinar: AABC Ask the Expert – Cliff Jack M.D., Mayo Clinic

On Nov. 14, 2018, Cliff Jack presented the NIA-AA revised research framework towards a biological definition of Alzheimer's disease, on which he is the first author on the publication. Slides from the webinar are available on the [AABC webpage](#).



General Postings to AABC's Membership

To post any general postings in future newsletters, please inform April Ross at aqross@alz.org

To help us grow AABC, please continue to introduce new members and/or companies to our group. We also welcome ideas and events for this newsletter so we can better serve you. Please send your suggestions to Dr. April Ross at aqross@alz.org.